FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1456-1462 November 11, 1993 Number 20 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Renal function declines progressively in patients who have diabetic nephropathy, and the decline may be slowed by antihypertensive drugs. The purpose of this study was to determine whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy.

Methods We performed a randomized, controlled trial comparing captopril with placebo in patients with insulin-dependent diabetes mellitus in whom urinary protein excretion was 500 mg per day and the serum creatinine concentration was 2.5 mg per deciliter (221 µmol per liter). Blood-pressure goals were defined to achieve control during a median follow-up of three years. The primary end point was a doubling of the base-line serum creatinine concentration.

Results Two hundred seven patients received captopril, and 202 placebo. Serum creatinine concentrations doubled in 25 patients in the captopril group, as compared with 43 patients in the placebo group (P =0.007). The associated reductions in risk of a doubling of the serum creatinine concentration were 48 percent in the captopril group as a whole, 76 percent in the subgroup with a base-line serum creatinine concentration of 2.0 mg per deciliter (177 µmol per liter), 55 percent in the subgroup with a concentration of 1.5 mg per deciliter (133 µmol per liter), and 17 percent in the subgroup with a concentration of 1.0 mg per deciliter (88.4 µmol per liter). The mean (±SD) rate of decline in creatinine clearance was 11 ±21 percent per year in the captopril group and 17 ±20 percent per year in the placebo group (P = 0.03). Among the patients whose base-line serum creatinine concentration was 1.5 mg per deciliter, creatinine clearance declined at a rate of 23 ±25 percent per year in the captopril group and at a rate of 37 ±25 percent per year in the placebo group (P = 0.01). Captopril treatment was associated with a 50 percent reduction in the risk of the combined end points of death, dialysis, and transplantation that was independent of the small disparity in blood pressure between the groups.

Conclusions Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.

Source Information

From the Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago (E.J.L., R.D.R.); the Department of Medicine, University of Iowa, Iowa City (L.G.H.); and the Biostatistics Center, George Washington University, Washington, D.C. (R.P.B.). Members of the Collaborative Study Group are listed in the Appendix.

Address reprint requests to Dr. Lewis at the Section of Nephrology, 1653 W. Congress Pky., Chicago, IL 60612.

Full Text of this Article

Related Letters:

The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
Fournier A., Lalau J.D., Lopez A., Marantz P. R., Parving H.-H., Lewis E. J., Bain R. P.
Extract | Full Text  
N Engl J Med 1994; 330:937-938, Mar 31, 1994. Correspondence

This article has been cited by other articles:

• Dobre, D., Lambers Heerspink, H. J., de Zeeuw, D. (2009). Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 11: F39-F46 [Abstract] [Full Text]  
• Philipp, T., Martinez, F., Geiger, H., Moulin, B., Mourad, G., Schmieder, R., Lievre, M., Heemann, U., Legendre, C. (2009). Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 0: gfp581v1-gfp581 [Abstract] [Full Text]  
• Ahmed, A. K., Kamath, N. S., El Kossi, M., El Nahas, A. M. (2009). The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 0: gfp511v1-gfp511 [Abstract] [Full Text]  
• Delea, T. E., Sofrygin, O., Palmer, J. L., Lau, H., Munk, V. C., Sung, J., Charney, A., Parving, H.-H., Sullivan, S. D. (2009). Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria. J. Am. Soc. Nephrol. 20: 2205-2213 [Abstract] [Full Text]  
• Kizu, A., Medici, D., Kalluri, R. (2009). Endothelial-Mesenchymal Transition as a Novel Mechanism for Generating Myofibroblasts during Diabetic Nephropathy. Am. J. Pathol. 175: 1371-1373 [Abstract] [Full Text]  
• Stevens, L. A., Schmid, C. H., Zhang, Y., Coresh, J., Manzi, J., Landis, R., Bakoush, O., Contreras, G., Genuth, S., Klintmalm, G. B., Poggio, E., Rossing, P., Rule, A. D., Weir, M. R., Kusek, J., Greene, T., Levey, A. S. (2009). Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant 0: gfp510v1-gfp510 [Abstract] [Full Text]  
• Haynes, R., Mason, P., Rahimi, K., Landray, M. J (2009). Dual blockade of the renin-angiotensin system: are two better than one?. Nephrol Dial Transplant 0: gfp458v1-gfp458 [Full Text]  
• Brown, N. J., Byiers, S., Carr, D., Maldonado, M., Warner, B. A. (2009). Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension 54: 516-523 [Abstract] [Full Text]  
• RamachandraRao, S. P., Zhu, Y., Ravasi, T., McGowan, T. A., Toh, I., Dunn, S. R., Okada, S., Shaw, M. A., Sharma, K. (2009). Pirfenidone Is Renoprotective in Diabetic Kidney Disease. J. Am. Soc. Nephrol. 20: 1765-1775 [Abstract] [Full Text]  
• Manno, C., Torres, D. D., Rossini, M., Pesce, F., Schena, F. P. (2009). Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 0: gfp356v1-gfp356 [Abstract] [Full Text]  
• Parving, H.-H., Brenner, B. M., McMurray, J. J.V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Pfeffer, M. A. (2009). Dual Renin-Angiotensin system blockade and kidney disease.. J Am Coll Cardiol 54: 278-279 [Full Text]  
• Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., Klein, R. (2009). Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. NEJM 361: 40-51 [Abstract] [Full Text]  
• Perkins, B. A., Aiello, L. P., Krolewski, A. S. (2009). Diabetes Complications and the Renin-Angiotensin System. NEJM 361: 83-85 [Full Text]  
• Schiffmann, R., Warnock, D. G., Banikazemi, M., Bultas, J., Linthorst, G. E., Packman, S., Sorensen, S. A., Wilcox, W. R., Desnick, R. J. (2009). Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24: 2102-2111 [Abstract] [Full Text]  
• Ku, E., Park, J., Vidhun, J., Campese, V. (2009). The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease. Arch Intern Med 169: 1015-1018 [Full Text]  
• Sever, P. S, Gradman, A. H, Azizi, M. (2009). Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of Renin-Angiotensin-Aldosterone System 10: 65-76 [Abstract]  
• O'Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., Larson, E. B. (2009). Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?. ANN INTERN MED 150: 717-724 [Abstract] [Full Text]  
• Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y., Castro, A. F. III, Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., Coresh, J., for the CKD-EPI (Chronic Kidney Disease Epidemiolo, (2009). A New Equation to Estimate Glomerular Filtration Rate. ANN INTERN MED 150: 604-612 [Abstract] [Full Text]  
• Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90 [Full Text]  
• 2005 WRITING COMMITTEE MEMBERS, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479 [Full Text]  
• Cortinovis, M., Perico, N., Cattaneo, D., Remuzzi, G. (2009). Aldosterone and progression of kidney disease. Ther Adv Cardiovasc Dis 3: 133-143 [Abstract]  
• Nuzum, D. S., Merz, T. (2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice 22: 135-148 [Abstract]  
• Fried, L. (2009). Are We Ready to Screen the General Population for Microalbuminuria?. J. Am. Soc. Nephrol. 20: 686-688 [Full Text]  
• de Zeeuw, D., Lambers-Heerspink, H. (2009). Drug Dosing for Renoprotection: Maybe It's Time for a Drug Efficacy-Safety Score?. J. Am. Soc. Nephrol. 20: 688-689 [Full Text]  
• Onuigbo, M.A.C. (2009). Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget--a call for more circumspection. QJM 102: 155-167 [Abstract] [Full Text]  
• Wenzel, R. R., Littke, T., Kuranoff, S., Jurgens, C., Bruck, H., Ritz, E., Philipp, T., Mitchell, A., for the SPP301 (Avosentan) Endothelin Antagonist E, (2009). Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria. J. Am. Soc. Nephrol. 20: 655-664 [Abstract] [Full Text]  
• Khavandi, K., Greenstein, A. S., Sonoyama, K., Withers, S., Price, A., Malik, R. A., Heagerty, A. M. (2009). Myogenic tone and small artery remodelling: insight into diabetic nephropathy. Nephrol Dial Transplant 24: 361-369 [Full Text]  
• Schernthaner, G. (2009). Kidney disease in diabetology: lessons from 2008. Nephrol Dial Transplant 24: 396-399 [Full Text]  
• Fried, L. F., Duckworth, W., Zhang, J. H., O'Connor, T., Brophy, M., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S., Warren, S. R., Peduzzi, P., for VA NEPHRON-D Investigators, (2009). Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). CJASN 4: 361-368 [Abstract] [Full Text]  
• den Hartog, J. R., Reese, P. P., Cizman, B., Feldman, H. I. (2009). The Costs and Benefits of Automatic Estimated Glomerular Filtration Rate Reporting. CJASN 4: 419-427 [Abstract] [Full Text]  
• Kim, S.-Y., Park, K.-H., Gul, R., Jang, K. Y., Kim, U.-H. (2009). Role of kidney ADP-ribosyl cyclase in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 296: F291-F297 [Abstract] [Full Text]  
• Kolesnyk, I., Noordzij, M., Dekker, F. W., Boeschoten, E. W., Krediet, R. T. (2009). A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 24: 272-277 [Abstract] [Full Text]  
• Ringholm Nielsen, L., Damm, P., Mathiesen, E. R. (2009). Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy: Effect of intensified antihypertensive therapy?. Diabetes Care 32: 38-44 [Abstract] [Full Text]  
• Delaney, A., Pellizzari, M., Speiser, P. W., Frank, G. R. (2009). Pitfalls in the Measurement of the Nocturnal Blood Pressure Dip in Adolescents with Type 1 Diabetes. Diabetes Care 32: 165-168 [Abstract] [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Kjeldsen, S. E., Aksnes, T. A., Fagard, R. H., Mancia, G. (2009). CHAPTER 13 Hypertension. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Bakker, S. J.L., Alkhalaf, A., Tarnow, L., Navis, G. (2008). Comment on: Wanic et al. (2008) Exclusion of Polymorphisms in Carnosinase Genes (CNDP1 and CNDP2) as a Cause of Diabetic Nephropathy in Type 1 Diabetes: Results of Large Case-Control and Follow-Up Studies: Diabetes 57:2547-2551, 2008. Diabetes 57: e16-e16 [Full Text]  
• Holdsworth, S. R., Summers, S. A. (2008). Role of Mast Cells in Progressive Renal Diseases. J. Am. Soc. Nephrol. 19: 2254-2261 [Abstract] [Full Text]  
• Radbill, B., Murphy, B., LeRoith, D. (2008). Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clin Proc. 83: 1373-1381 [Abstract] [Full Text]  
• Wright, J., Vardhan, A. (2008). Review: The problem of diabetic nephropathy and practical prevention of its progression. British Journal of Diabetes & Vascular Disease 8: 272-277 [Abstract]  
• Sloan, F. A., Belsky, D., Ruiz, D. Jr, Lee, P. (2008). Changes in Incidence of Diabetes Mellitus-Related Eye Disease Among US Elderly Persons, 1994-2005. Arch Ophthalmol 126: 1548-1553 [Abstract] [Full Text]  
• Spurney, R. F., Coffman, T. M. (2008). Stressed-out Podocytes in Diabetes?. J. Am. Soc. Nephrol. 19: 2035-2037 [Full Text]  
• Gaarkeuken, H., Siezenga, M. A., Zuidwijk, K., van Kooten, C., Rabelink, T. J., Daha, M. R., Berger, S. P. (2008). Complement activation by tubular cells is mediated by properdin binding. Am. J. Physiol. Renal Physiol. 295: F1397-F1403 [Abstract] [Full Text]  
• Descorbeth, M., Anand-Srivastava, M. B. (2008). High glucose increases the expression of Gq/11{alpha} and PLC-{beta} proteins and associated signaling in vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 295: H2135-H2142 [Abstract] [Full Text]  
• SCHREIBER, M. J. JR, (2008). Preventing renal disease progression: Can complete renin-angiotensin-aldosterone blockade work?. Cleveland Clinic Journal of Medicine 75: 699-704 [Full Text]  
• HIRSCH, S. (2008). An update on proteinuric chronic kidney disease: The dual-goal approach. Cleveland Clinic Journal of Medicine 75: 705-713 [Abstract] [Full Text]  
• Kopple, J. D (2008). Do low-protein diets retard the loss of kidney function in patients with diabetic nephropathy?. Am. J. Clin. Nutr. 88: 593-594 [Full Text]  
• Hadjadj, S., Fumeron, F., Roussel, R., Saulnier, P.-J., Gallois, Y., Ankotche, A., Travert, F., Khalil, C. A., Miot, A., Alhenc-Gelas, F., Lievre, M., Marre, M., on behalf of the DIABHYCAR, DIAB2NEPHROGENE, and S, (2008). Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects: Results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies . Diabetes Care 31: 1847-1852 [Abstract] [Full Text]  
• Melamed, M. L., Bauer, C., Hostetter, T. H. (2008). eGFR: Is It Ready for Early Identification of CKD?. CJASN 3: 1569-1572 [Abstract] [Full Text]  
• Chun, T.-Y., Chander, P. N., Kim, J.-W., Pratt, J. H., Stier, C. T. Jr. (2008). Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Endocrinol. Metab. 295: E305-E312 [Abstract] [Full Text]  
• Chapman, A. B. (2008). Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease: Insights from the CRISP and HALT-PKD Studies. CJASN 3: 1197-1204 [Abstract] [Full Text]  
• Almerie, M Q, Williams, R M, Acerini, C L (2008). SHOULD ANGIOTENSIN CONVERTING ENZYME INHIBITORS BE USED IN CHILDREN WITH TYPE 1 DIABETES AND MICROALBUMINURIA?. Arch. Dis. Child. 93: 633-635 [Full Text]  
• Feldman, D. L., Jin, L., Xuan, H., Contrepas, A., Zhou, Y., Webb, R. L., Mueller, D. N., Feldt, S., Cumin, F., Maniara, W., Persohn, E., Schuetz, H., Jan Danser, A.H., Nguyen, G. (2008). Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats. Hypertension 52: 130-136 [Abstract] [Full Text]  
• Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K., the AVOID Study Investigators, (2008). Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. NEJM 358: 2433-2446 [Abstract] [Full Text]  
• Stevens, V. A, Saad, S., Poronnik, P., Fenton-Lee, C. A, Polhill, T. S, Pollock, C. A (2008). The role of SGK-1 in angiotensin II-mediated sodium reabsorption in human proximal tubular cells. Nephrol Dial Transplant 23: 1834-1843 [Abstract] [Full Text]  
• Mima, A., Arai, H., Matsubara, T., Abe, H., Nagai, K., Tamura, Y., Torikoshi, K., Araki, M., Kanamori, H., Takahashi, T., Tominaga, T., Matsuura, M., Iehara, N., Fukatsu, A., Kita, T., Doi, T. (2008). Urinary Smad1 Is a Novel Marker to Predict Later Onset of Mesangial Matrix Expansion in Diabetic Nephropathy. Diabetes 57: 1712-1722 [Abstract] [Full Text]  
• Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V., Costantini, M., Sharma, S. K., Perna, A., Remuzzi, G. (2008). Role of Remission Clinics in the Longitudinal Treatment of CKD. J. Am. Soc. Nephrol. 19: 1213-1224 [Full Text]  
• Peng, F., Wu, D., Gao, B., Ingram, A. J., Zhang, B., Chorneyko, K., McKenzie, R., Krepinsky, J. C. (2008). RhoA/Rho-Kinase Contribute to the Pathogenesis of Diabetic Renal Disease. Diabetes 57: 1683-1692 [Abstract] [Full Text]  
• Dubel, G. J, Murphy, T. P (2008). The role of percutaneous revascularization for renal artery stenosis. Vasc Med 13: 141-156 [Abstract]  
• Bauer, C., Melamed, M. L., Hostetter, T. H. (2008). Staging of Chronic Kidney Disease: Time for a Course Correction. J. Am. Soc. Nephrol. 19: 844-846 [Abstract] [Full Text]  
• Coffman, T. M., Crowley, S. D. (2008). Kidney in Hypertension: Guyton Redux. Hypertension 51: 811-816 [Full Text]  
• Arfa, I., Abid, A., Nouira, S., Elloumi-Zghal, H., Malouche, D., Mannai, I., Zorgati, M. M., Ben Alaya, N., Rebai, A., Zouari, B., Ben Ammar, S., Ben Rayana, M. C., Hmida, S., Blousa-Chabchoub, S., Abdelhak, S. (2008). Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients. Journal of Renin-Angiotensin-Aldosterone System 9: 32-36 [Abstract]  
• Jaar, B. G., Khatib, R., Plantinga, L., Boulware, L. E., Powe, N. R. (2008). Principles of Screening for Chronic Kidney Disease. CJASN 3: 601-609 [Full Text]  
• Xu, Z.-G., Yuan, H., Lanting, L., Li, S.-L., Wang, M., Shanmugam, N., Kato, M., Adler, S. G., Reddy, M. A., Natarajan, R. (2008). Products of 12/15-Lipoxygenase Upregulate the Angiotensin II Receptor. J. Am. Soc. Nephrol. 19: 559-569 [Abstract] [Full Text]  
• Nakhoul, F., Khankin, E., Yaccob, A., Kawachi, H., Karram, T., Awaad, H., Nakhoul, N., Hoffman, A., Abassi, Z. (2008). Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. Am. J. Physiol. Renal Physiol. 294: F628-F637 [Abstract] [Full Text]  
• Gradman, A. H., Kad, R. (2008). Renin inhibition in hypertension.. J Am Coll Cardiol 51: 519-528 [Abstract] [Full Text]  
• Steinman, T. I. (2008). Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 431-433 [Full Text]  
• de Zeeuw, D., Raz, I. (2008). Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes. Diabetes Care 31: S190-S193 [Full Text]  
• Knoll, G. A., Cantarovitch, M., Cole, E., Gill, J., Gourishankar, S., Holland, D., Kiberd, B., Muirhead, N., Prasad, R., Tibbles, L. A., Treleaven, D., Fergusson, D. (2008). The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design. Nephrol Dial Transplant 23: 354-358 [Abstract] [Full Text]  
• Steigerwalt, S. (2008). Management of Hypertension in Diabetic Patients With Chronic Kidney Disease. Diabetes Spectr. 21: 30-36 [Abstract] [Full Text]  
• Lely, A. T., van der Kleij, F. G.H., Kistemaker, T. J., Apperloo, A. J., de Jong, P. E., de Zeeuw, D., Navis, G. (2008). Impact of the Preintervention Rate of Renal Function Decline on Outcome of Renoprotective Intervention. CJASN 3: 54-60 [Abstract] [Full Text]  
• American Diabetes Association, (2008). Standards of Medical Care in Diabetes--2008. Diabetes Care 31: S12-S54 [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2007). Health of Previously Uninsured Adults After Acquiring Medicare Coverage. JAMA 298: 2886-2894 [Abstract] [Full Text]  
• Burnier, M. (2007). Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective. Journal of Renin-Angiotensin-Aldosterone System 8: 208-211  
• Siragy, H. M. (2007). Angiotensin AT1 and AT2 receptors the battle for health and disease. Nephrol Dial Transplant 22: 3128-3130 [Full Text]  
• Authors/Task Force Members, , Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S. G., Pyorala, K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Scholte op Reimer, W., Weissberg, P., Wood, D., Yarnell, J., Zamorano, J. L., Other experts who contributed to parts of the guid, , Walma, E., Fitzgerald, T., Cooney, M. T., Dudina, A., European Society of Cardiology (ESC) Committee for, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Funck-Brentano, C., Filippatos, G., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document reviewers:, , Hellemans, I., Altiner, A., Bonora, E., Durrington, P. N., Fagard, R., Giampaoli, S., Hemingway, H., Hakansson, J., Kjeldsen, S. E., Larsen, M. L., Mancia, G., Manolis, A. J., Orth-Gomer, K., Pedersen, T., Rayner, M., Ryden, L., Sammut, M., Schneiderman, N., Stalenhoef, A. F., Tokgozoglu, L., Wiklund, O., Zampelas, A. (2007). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 28: 2375-2414 [Full Text]  
• Stevens, L. A., Coresh, J., Feldman, H. I., Greene, T., Lash, J. P., Nelson, R. G., Rahman, M., Deysher, A. E., Zhang, Y., Schmid, C. H., Levey, A. S. (2007). Evaluation of the Modification of Diet in Renal Disease Study Equation in a Large Diverse Population. J. Am. Soc. Nephrol. 18: 2749-2757 [Abstract] [Full Text]  
• Tan, Y., Keum, J.-S., Wang, B., McHenry, M. B., Lipsitz, S. R., Jaffa, A. A. (2007). Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 293: F1026-F1035 [Abstract] [Full Text]  
• Ardissino, G., Vigano, S., Testa, S., Dacco, V., Paglialonga, F., Leoni, A., Belingheri, M., Avolio, L., Ciofani, A., Claris-Appiani, A., Cusi, D., Edefonti, A., Ammenti, A., Cecconi, M., Fede, C., Ghio, L., La Manna, A., Maringhini, S., Papalia, T., Pela, I., Pisanello, L., Ratsch, I. M., on behalf of the ItalKid Project, (2007). No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy report from the ItalKid Project database. Nephrol Dial Transplant 22: 2525-2530 [Abstract] [Full Text]  
• Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R., Kopp, J. B. (2007). Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis. CJASN 2: 906-913 [Abstract] [Full Text]  
• Borer, J. S. (2007). Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases. Eur Heart J Suppl 9: E2-E9 [Abstract] [Full Text]  
• Chobanian, A. V. (2007). Isolated Systolic Hypertension in the Elderly. NEJM 357: 789-796 [Full Text]  
• Wong, D. W., Oudit, G. Y., Reich, H., Kassiri, Z., Zhou, J., Liu, Q. C., Backx, P. H., Penninger, J. M., Herzenberg, A. M., Scholey, J. W. (2007). Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. Am. J. Pathol. 171: 438-451 [Abstract] [Full Text]  
• Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S. (2007). REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Hypertension 50: e28-e55 [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2007). Use of Health Services by Previously Uninsured Medicare Beneficiaries. NEJM 357: 143-153 [Abstract] [Full Text]  
• Cavanaugh, K. L. (2007). Diabetes Management Issues for Patients With Chronic Kidney Disease. Clin. Diabetes 25: 90-97 [Abstract] [Full Text]  
• Boulanger, H., Mansouri, R., Gautier, J. F., Glotz, D. (2007). Reply--PPAR agonists in diabetic nephropathy. Nephrol Dial Transplant 22: 2095-2096 [Full Text]